These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 33788326)

  • 1. The effect of needle and syringe program and opioid agonist therapy on the risk of HIV, hepatitis B and C virus infection for people who inject drugs in Amsterdam, the Netherlands: findings from an emulated target trial.
    van Santen DK; Boyd A; Matser A; Maher L; Hickman M; Lodi S; Prins M
    Addiction; 2021 Nov; 116(11):3115-3126. PubMed ID: 33788326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials.
    van Santen DK; Lodi S; Dietze P; van den Boom W; Hayashi K; Dong H; Cui Z; Maher L; Hickman M; Boyd A; Prins M
    Addiction; 2023 Jun; 118(6):1116-1126. PubMed ID: 36710474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons learned from the Amsterdam Cohort Studies among people who use drugs: a historical perspective.
    van Santen DK; Coutinho RA; van den Hoek A; van Brussel G; Buster M; Prins M
    Harm Reduct J; 2021 Jan; 18(1):2. PubMed ID: 33407562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
    Van Den Berg C; Smit C; Van Brussel G; Coutinho R; Prins M;
    Addiction; 2007 Sep; 102(9):1454-62. PubMed ID: 17697278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
    Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
    Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania.
    Fraser H; Stone J; Wisse E; Sambu V; Mfisi P; Duran IJ; Soriano MA; Walker JG; Makere N; Luhmann N; Kafura W; Nouvellet M; Ragi A; Mundia B; Vickerman P
    J Int AIDS Soc; 2021 Oct; 24(10):e25817. PubMed ID: 34661964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Harm Reduction Coverage and Hepatitis C Incidence: Findings From a Cohort of People Who Inject Drugs.
    Minoyan N; Artenie AA; Zang G; Jutras-Aswad D; Turcotte MÈ; Bruneau J
    Am J Prev Med; 2020 Jun; 58(6):845-853. PubMed ID: 32444003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of needle and syringe Programmes in people who inject drugs - An overview of systematic reviews.
    Fernandes RM; Cary M; Duarte G; Jesus G; Alarcão J; Torre C; Costa S; Costa J; Carneiro AV
    BMC Public Health; 2017 Apr; 17(1):309. PubMed ID: 28399843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of injecting drug use and HIV, hepatitis B, and hepatitis C in people who inject drugs in the Eastern Mediterranean region: a systematic review and meta-analysis.
    Aghaei AM; Gholami J; Sangchooli A; Rostam-Abadi Y; Olamazadeh S; Ardeshir M; Baheshmat S; Shadloo B; Taj M; Saeed K; Rahimi-Movaghar A
    Lancet Glob Health; 2023 Aug; 11(8):e1225-e1237. PubMed ID: 37474230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.
    Fraser H; Mukandavire C; Martin NK; Goldberg D; Palmateer N; Munro A; Taylor A; Hickman M; Hutchinson S; Vickerman P
    Addiction; 2018 Nov; 113(11):2118-2131. PubMed ID: 29781207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal.
    Neaigus A; Zhao M; Gyarmathy VA; Cisek L; Friedman SR; Baxter RC
    J Urban Health; 2008 May; 85(3):309-22. PubMed ID: 18340537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and meta-analysis.
    Platt L; Minozzi S; Reed J; Vickerman P; Hagan H; French C; Jordan A; Degenhardt L; Hope V; Hutchinson S; Maher L; Palmateer N; Taylor A; Bruneau J; Hickman M
    Addiction; 2018 Mar; 113(3):545-563. PubMed ID: 28891267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High levels of used syringe use and unsafe sex among people who inject drugs in Kumasi, Ghana: an urgent call for a comprehensive harm reduction approach.
    Messersmith LJ; Adjei R; Beard J; Bazzi AR; Earlywine JJ; Darko E; Agyarko-Poku T; Asafo MK; Bempah SA; Adu-Sarkodie Y
    Harm Reduct J; 2021 Jun; 18(1):62. PubMed ID: 34112187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interventions to prevent HIV and Hepatitis C among people who inject drugs: Latest evidence of effectiveness from a systematic review (2011 to 2020).
    Palmateer N; Hamill V; Bergenstrom A; Bloomfield H; Gordon L; Stone J; Fraser H; Seyler T; Duan Y; Tran R; Trayner K; Biggam C; Smith S; Vickerman P; Hickman M; Hutchinson S
    Int J Drug Policy; 2022 Nov; 109():103872. PubMed ID: 36202039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of structural-level needle/syringe programs to reduce HCV and HIV infection among people who inject drugs: a systematic review.
    Abdul-Quader AS; Feelemyer J; Modi S; Stein ES; Briceno A; Semaan S; Horvath T; Kennedy GE; Des Jarlais DC
    AIDS Behav; 2013 Nov; 17(9):2878-92. PubMed ID: 23975473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis.
    Bao Y; Larney S; Peacock A; Colledge S; Grebely J; Hickman M; Degenhardt L; Leung J
    Int J Drug Policy; 2019 Aug; 70():87-93. PubMed ID: 31125802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: a systematic review.
    Des Jarlais DC; Feelemyer JP; Modi SN; Abdul-Quader A; Hagan H
    BMC Public Health; 2013 Jan; 13():53. PubMed ID: 23332005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining risk behavior and syringe coverage among people who inject drugs accessing a syringe services program: A latent class analysis.
    Bartholomew TS; Tookes HE; Bullock C; Onugha J; Forrest DW; Feaster DJ
    Int J Drug Policy; 2020 Apr; 78():102716. PubMed ID: 32146348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya.
    Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P
    AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.